SBIR Phase I: Non-pharmaceutical, light and ultrasound combination therapy to prevent SSI's and HAI's

SBIR 第一阶段：非药物、光和超声联合疗法，预防 SSI 和 HAI

• 批准号: 2025728
• 负责人: Vipula Tailor
• 金额: $ 25.37万
• 依托单位: SONIX MEDICAL DEVICES INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-01 至 2021-08-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2025728&HistoricalAwards=false
• 关键词: SBIR; Phase; Non; pharmaceutical; light

The broader impact/commercial the potential of this Small Business Innovation Research (SBIR) Phase I project is significant reduction in suffering and healthcare costs from the incidence of Surgical Site Infections (SSIs), Hospital Acquired Infections (HAIs), and Superbugs. This project will provide many societal benefits: improved disaster care prior to hospitalization; better in-field military injury outcomes; improved infection care in underdeveloped nations with limited access to hospitals and clinics, and others. Costs of HAIs and SSIs currently exceed $41B worldwide. A recent estimate indicates that failing to tackle antibiotic resistance could lead to over 10M deaths annually, and millions in cumulative economic damage. The proposed technology is an infection treatment that does not use antibiotics. As an alternative, this project will offer a non-pharmaceutical solution providing cost-effective treatments that reduce the clinical use of antibiotics. This project will provide a reduction in patient suffering, improved medical outcomes, and reduced overall healthcare costs.This Small Business Innovation Research (SBIR) Phase I project will develop a non-pharmaceutical therapy that selectively kills bacteria and viruses and prevents SSI’s and HAI’s and does not induce further antimicrobial resistance. The project focuses on combining and simultaneous applying specific wavelengths of light and sound frequency resulting in a novel therapeutic dose to kill bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA). The technology can be used pre-surgery to disinfect body areas where the surgery will be performed, and post-surgery to prevent infections at surgical sites. The innovative combination of specific wavelengths of light and sound frequency activates a unique biochemical mechanism to kill bacteria from within. The research will identify ideal materials that will transmit both light and sound energies efficiently whilst meeting safety, efficacy, and ergonomic configurations for proposed applications. The aim is to also find optimal treatment times to treat different areas of the body for specific bacterial infections.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

小企业创新研究(SBIR)第一阶段项目的更广泛影响/商业潜力在于，手术部位感染(SSI)、医院获得性感染(HAI)和超级细菌的发生率显著降低了患者的痛苦和医疗成本。该项目将提供许多社会效益：改善住院前的灾害护理；改善战地军事伤害结果；改善不发达国家的感染护理，因为这些国家获得医院和诊所的机会有限，等等。目前，全球人类免疫缺陷病毒和SSI的成本超过410亿美元。最近的一项估计表明，如果不能解决抗生素耐药性问题，每年可能导致超过1000万人死亡，并造成数百万人的累积经济损失。拟议的技术是一种不使用抗生素的感染治疗方法。作为另一种选择，该项目将提供一种非药物解决方案，提供成本效益高的治疗方法，减少抗生素的临床使用。这个项目将减少患者的痛苦，改善医疗结果，降低总体医疗成本。这个小企业创新研究(SBIR)第一阶段项目将开发一种非药物疗法，有选择性地杀死细菌和病毒，预防SSI和HAI，并且不会导致进一步的抗菌素耐药性。该项目的重点是结合并同时应用特定波长的光和声频率，从而产生一种新的治疗剂量来杀死细菌，包括耐甲氧西林金黄色葡萄球菌(MRSA)。这项技术可以在手术前用于对将要进行手术的身体区域进行消毒，并在手术后用于防止手术部位的感染。特定波长的光和声音频率的创新组合激活了一种独特的生化机制，从内部杀死细菌。这项研究将确定理想的材料，这些材料将有效地传输光能和声能，同时满足拟议应用的安全性、有效性和人体工学配置。这个奖项反映了NSF的法定使命，通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。